Loading data for PRQR — first visit, this takes a few seconds.

알림

ProQR Therapeutics N.V. (PRQR)

NasdaqCM: PRQR · 실시간 가격 · USD

1.92

+0.07 (3.78%)

종가 기준: Aug 19, 2026, 8:00 PM

2.22

+0.04%

애프터마켓: 6:15 PM

3.78% (1D)

데이터 없음

매수호가	1.38
시가총액	313.28M
매출 (ttm)	18.42M
순이익 (ttm)	-42.04M
베타	0.03
EPS (ttm)	-0.46
P/E (ttm)	n/a
선행 P/E	-3.99
P/B (ttm)	5.38
P/S (ttm)	17.01
Earnings Date	Aug 13, 2026

매도호가	2.35
거래량	487,167
평균 거래량 (20일)	1,006,856
시가	1.85
전일 종가	1.85
일중 범위	1.83 - 1.95
52주 범위	1.33 - 3.10
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

PRQR 소개

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targe...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Sep 18, 2014

직원 수 186

상장 거래소 NasdaqCM

티커 PRQR

웹사이트 https://www.proqr.com

전체 기업 정보

재무 실적

2025년 ProQR Therapeutics의 매출은 15.91M로, 전년 18.91M 대비 -15.86% 감소했습니다. 순이익은 -42.18M로, 51.94% 증가했습니다.

재무제표

어닝 서프라이즈

ProQR Therapeutics가 May 12, 2026에 분기 실적을 발표했습니다:

매출 $2.03M 예상치 하회 $0, 및 -55.01% 전년 대비 감소.

EPS -0.15 예상치 상회 0.03, 및 -36.36% 전년 대비 감소.

다음 실적 발표

ProQR Therapeutics N.V.의 실적 발표 예정일은 Aug 13, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2개월 전 · Simply Wall St.

Undervalued Penny Stocks To Consider In June 2026

Over the last 7 days, the United States market has dropped 2.5%, but it remains up 23% over the past year with earnings forecasted to grow by 17% annually. For investors looking beyond well-known stoc...

3개월 전 · Simply Wall St.

ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%

Today is shaping up negative for ProQR Therapeutics N.V. ( NASDAQ:PRQR ) shareholders, with the analysts delivering a...

3개월 전 · Zacks

Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates

Kamada (KMDA) delivered earnings and revenue surprises of -40.02% and -2.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

3개월 전 · Zacks

Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline

ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3개월 전 · Simply Wall St.

3 Promising Penny Stocks With Market Caps Up To $600M

The market has climbed 1.8% in the last 7 days and is up 30% over the past year, with earnings projected to grow by 16% annually. Penny stocks, while a somewhat outdated term, continue to represent in...

2 페이지 중 1

ProQR Therapeutics N.V. (PRQR)